Watch this webinar exploring real challenges and solutions for generating patient-centered real-world evidence (RWE) in the context of rare diseases to support clinical development through commercial post-approval.
Inspire, the leading patient engagement and real-world evidence platform, brings together industry experts Megan Gower, PharmD and Edward Chou, PhD at Takeda who share their expertise, experiences, and lessons learned in this field.
Rare diseases pose unique challenges when it comes to generating robust and reliable evidence due to their low prevalence and limited available data. However, patient-centered RWE is increasingly important at every phase of drug development and post approval marketing. During this webinar, industry experts discuss challenges and potential solutions for collecting, analyzing, and interpreting patient-centered real-world data.
Key Topics Include:
- Understand common challenges associated with access to rare disease patients necessary for generating patient-centered real-world evidence.
- Learn about best practices to ensure high quality real-world data, including methodologies and innovative strategies for data collection and analysis.
- Discover the benefits of patient engagement and collaboration in enhancing real-world evidence generation.
Presenters
Richard Tsai
Richard Tsai, Senior Vice President of Real-World Evidence at Inspire, is a life sciences and digital health executive with more than 20 years of experience in marketing, product development and commercial strategy. In addition to overseeing Real-World Evidence, Richard is responsible for developing Inspire’s patient-centered real-world data and engagement platform, which empowers patients and caregivers across their medical journey and accelerates gathering of real world insights of diseases or therapeutics for researchers. Prior to joining Inspire, he held positions at Thermo Fisher Scientific, Rare Genomics Institute, and Hopkins Biotech Network. Richard completed his undergraduate degree at the University of California, Riverside, and a Masters Degree in Biotechnology, Business Enterprise and Regulatory Affairs from Johns Hopkins University.
Megan Gower
Dr. Megan Gower serves as clinical scientist on the Takeda US Medical Value and Evidence Generation Clinical Research team. In her role at Takeda, Megan oversees the development of clinical trial designs (phase IV and collaborative), study conduct, synopsis and protocol development and project alignment with therapeutic area strategy (Immunology-PDT, Transplant, Gastroenterology, Rare Endocrine). Prior to joining Takeda, she served as a clinical scientist in early-stage clinical development. Megan was responsible for various clinical scientist activities to support product development from FIH studies through NDA submission and beyond. Megan earned her undergraduate degree in chemistry from the University of South Florida, received her Doctor of Pharmacy (PharmD) from South College School of Pharmacy, and completed a fellowship in Clinical Research and Drug Development with the University of North Carolina at Chapel Hill and PPD. She also has experience in real-world evidence analysis, competitive intelligence, platform development and functionality assessment.
Edward Chou
Dr. Edward Chou is an Associate Director on the Takeda US Medical Value and Evidence Generation Health Economics and Outcomes Research team. He currently leads and executes three marquee research programs to deliver rigorous real-world evidence for US HEOR priority strategy needs. Prior to joining Takeda, Edward was a university faculty member and academic researcher studying disease management strategies and patient outcomes of multiple chronic conditions (cancers, diabetes, cardiovascular diseases) with a focus on health disparities. He mentored PhD/MS/PharmD students and medical residents/fellows, and taught graduate courses in research methods, biostatistics, pharmacoepidemiology, social and behavioral theories, and health program evaluation. Edward received his bachelor’s degree in pharmacy from National Taiwan University, his MS in biostatistics from the University of Michigan School of Public Health, and his PhD in health services research from the University of Wisconsin-Madison. He also completed a post-doctoral fellowship in health economics and outcomes research with Duke Clinical Research Institute and Novartis.
Sponsor
